Proctor Hospital

Running trials

• Active, not recruiting

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· Phase 3· Source

• Active, not recruiting

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· Phase 3· Source

• Active, not recruiting

  Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT01708954· Phase 2· Source

• Active, not recruiting

  Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

  NCT01575548· Phase 3· Source

• Active, not recruiting

  Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338· Phase 3· Source

• Active, not recruiting

  Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

  NCT01169337· Phase 3· Source

• Active, not recruiting

  Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

  NCT01134614· Phase 2· Source

• Active, not recruiting

  Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

  NCT01081262· Phase 3· Source

• Active, not recruiting

  Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712· Phase 3· Source

• Active, not recruiting

  Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

  NCT01142388· Phase 2· Source

• Active, not recruiting

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· Phase 3· Source

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228· Phase 3· Source

• Active, not recruiting

  Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT00602641· Phase 3· Source

• Active, not recruiting

  Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

  NCT00569127· Phase 3· Source

• Active, not recruiting

  Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

  NCT00114101· Phase 3· Source

• Active, not recruiting

  Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

  NCT00070499· Phase 2· Source

• Active, not recruiting

  Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

  NCT00048958· Source

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390· Phase 2· Source

• Completed

  Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875· Phase 2· Source

• Completed

  Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01708941· Phase 2· Source

• Completed

  S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691· Phase 3· Source

• Completed

  S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

  NCT01359592· Phase 2· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· Source

• Completed

  Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

  NCT01251861· Phase 2· Source

• Completed

  Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900· Phase 3· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· Source

• Completed

  Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

  NCT00309985· Phase 3· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· Source

• Completed

  S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

  NCT00006721· Phase 3· Source